0001437749-21-026247.txt : 20211112 0001437749-21-026247.hdr.sgml : 20211112 20211112063511 ACCESSION NUMBER: 0001437749-21-026247 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20211111 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211112 DATE AS OF CHANGE: 20211112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 211399319 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 8-K 1 bioli20211111_8k.htm FORM 8-K bioli20211111_8k.htm
false 0000834365 0000834365 2021-11-11 2021-11-11
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 11, 2021
 
BIOLIFE SOLUTIONS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
  
001-36362
  
94-3076866
(State or other jurisdiction of
incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)
 
3303 Monte Villa Parkway, Suite 310
Bothell, WA 98021
(Address of principal executive offices) (Zip Code)
 
Registrant’s telephone number, including area code: (425) 402-1400
 
N/A
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading symbol
Name of exchange on which registered
BioLife Solutions, Inc. Common Shares
BLFS
NASDAQ Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 2.02         Results of Operations and Financial Condition.
 
On November 11, 2021, BioLife Solutions, Inc. (the “Company”) issued a press release announcing the financial results and operational highlights for the third quarter ended September 30, 2021. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.
 
Item 9.01         Financial Statements and Exhibits.
 
(d) Exhibits
 
Exhibit No.
  
Description
99.1
  
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
SIGNATURE
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
BioLife Solutions, Inc.
  
     
Date: November 12, 2021
By:
/s/ Roderick de Greef
  
   
Name: Roderick de Greef
Title: President and Chief Operating Officer
  
 
 
 EX-99.1 2 ex_306474.htm EXHIBIT 99.1 ex_306474.htm

Exhibit 99.1

 

a01.jpg
 
a02.jpg

 

BioLife Solutions Announces Third Quarter 2021 Financial Results

 

Total revenue up 200% over Q3 2020; organic revenue up 37% over Q3 2020 driven by 49% growth in media revenue

 

Raises full-year 2021 revenue guidance to $115 to $119 million, reflecting strong demand for proprietary biopreservation media products

 

Conference call begins at 4:30 p.m. Eastern time today

 

BOTHELL, Wash. (November 11, 2021) – BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced financial results for the three and nine months ended September 30, 2021.

 

Mike Rice, Chairman and CEO, commented, “Demand for our proprietary biopreservation media products continued to accelerate in Q3, with nearly 50% year over year growth and 14% sequential growth. We estimate that our media products have been incorporated into at least 530 customer clinical applications, most of these being cell and gene therapy clinical trials. We remain confident in achieving our financial performance goals of $250 million in revenue and adjusted EBITDA of 30+% within the next three to four years.”

 

Third Quarter 2021 and Recent Operating Highlights

 

 

●

Completed the acquisition of Sexton Biotechnologies, Inc., which became a wholly owned subsidiary on September 1, 2021.

 

 

●

Gained at least 230 new customers including 30 using biopreservation media, 6 using ThawSTAR® systems, 11 using evo® cold chain management services, 16 using CBS freezers and accessories, 140 using Stirling freezers and accessories, 15 using SciSafe® biologic storage services and 12 now using Sexton cell processing products. We believe the actual number of new customers to be significantly higher, considering the breadth of our global distributor network.

 

 

●

Processed 20 new U.S. FDA Drug Master File cross-reference requests, indicating the planned use of CryoStor® or HypoThermosol® in pending cell and gene therapy clinical trials. To date, our biopreservation media products have been used in more than 530 custom clinical applications and are embedded in the manufacturing process of seven approved cell or gene therapies. We estimate potential annual media revenue per customer application to range from $500,000 to $2,000,000 if regulatory approvals are received.

 

 
 
 

 

a01.jpg
 
a02.jpg

 

Third Quarter 2021 Financial Highlights

 

BioLife Solutions is presenting various financial metrics under U.S. Generally Accepted Accounting Principles (GAAP) and as adjusted (non-GAAP). A reconciliation of GAAP to non-GAAP metrics appears at the end of this news release.

 

 

REVENUE

 

 

●

Total revenue for the third quarter of 2021 was $33.8 million, an increase of 200% from $11.3 million for the third quarter of 2020 and organic revenue growth was up 37%.
 

o

Cell processing platform revenue was $11.5 million, up 55% over the third quarter of 2020.
 

o

Freezers and Thaw Systems platform revenue was $17.6 million, up $14.2 million over the same period in 2020.
 

o

Storage and Cold Chain Services platform revenue was $4.7 million, up $4.2 million over the same period in 2020.

 

 

●

Total revenue for the nine months ended September 30, 2021 was $81.9 million, an increase of 145% from $33.4 million for the nine months ended September 30, 2020 and organic revenue growth was up 34%.
 

o

Cell processing platform revenue was $30.1 million, up 32% over the same period in 2020.
 

o

Freezers and Thaw Systems platform revenue was $40.0 million, up $30.8 million over the same period in 2020.
 

o

Storage and Cold Chain Services platform revenue was $11.7 million, up $10.3 million over the same period in 2020.

 

GROSS MARGIN

 

 

●

Gross margin (GAAP) for the third quarter of 2021 was 25% compared with 52% for the third quarter of 2020. Adjusted gross margin (non-GAAP) for the third quarter of 2021 was 28% compared with 57% for the third quarter of 2020. The decline in gross margin resulted from charges of $4.3 million, or 13% of total revenue, related to increased warranty expense, supply chain surcharges, and scrap associated with the Stirling ULT freezers. Excluding the $4.3 million of charges, adjusted gross margin was approximately 40%.

 

Page 2 of 13
 

 

a01.jpg
 
a02.jpg

 

 

●

While posting this outstanding topline performance, we experienced some operational issues related to the Stirling ULT products. Our operations team, now led by Rod de Greef in his new role as President and Chief Operating Officer, is focused on more robust supply chain management, while our quality team is implementing new quality assurance initiatives for our ULT freezer products; both of which will improve gross margin in future periods.

 

 

●

Gross margin (GAAP) for the nine months ended September 30, 2021 was 36% compared with 53% for the nine months ended September 30, 2020. Adjusted gross margin (non-GAAP) for the nine months ended September 30, 2021 was 39% compared with 60% for the nine months ended September 30, 2020. Gross margin for the nine months was also negatively impacted by the Stirling ULT freezer issues cited above.

 

OPERATING EXPENSE

 

 

●

Operating expense (GAAP) for the third quarter of 2021 was $45.0 million compared with $12.5 million for the third quarter of 2020. Adjusted operating expense (non-GAAP) for the third quarter of 2021 was $17.4 million compared with $6.8 million for the third quarter 2020.

 

 

●

Operating expense (GAAP) for the nine months ended September 30, 2021 was $98.5 million compared with $34.2 million for the nine months ended September 30, 2020. Adjusted operating expense (non-GAAP) for the nine months ended September 30, 2021 was $39.5 million compared with $19.3 million for the nine months ended September 30, 2020.

 

 

●

The increase in operating expense was primarily due to the acquisitions of Stirling, SciSafe, and Sexton and higher personnel costs, including non-cash stock compensation expense.

 

OPERATING INCOME/(LOSS)

 

 

●

Operating loss (GAAP) for the third quarter of 2021 was $11.2 million compared with $1.2 million for the third quarter of 2020. Adjusted operating loss (non-GAAP) for the third quarter of 2021 was $8.1 million compared with $359,000 for the third quarter of 2020.

 

 

●

Operating loss (GAAP) for the nine months ended September 30, 2021 was $16.7 million compared with $832,000 for the nine months ended September 30, 2020. Adjusted operating loss (non-GAAP) for the nine months ended September 30, 2021 was $7.5 million compared with adjusted operating income of $547,000 for the nine months ended September 30, 2020.

 

Page 3 of 13
 

 

a01.jpg
 
a02.jpg

 

NET INCOME/(LOSS)

 

 

●

Net income (GAAP) for the third quarter of 2021 was $79,000 compared with net loss of $1.1 million for the third quarter of 2020. Adjusted net loss (non-GAAP) for the third quarter of 2021 was $8.3 million compared with adjusted net loss of $346,000 for the third quarter of 2020.

 

 

●

Net income (GAAP) for the nine months ended September 30, 2021 was $6.8 million compared with $4.8 million for the nine months ended September 30, 2020. Adjusted net loss (non-GAAP) for the nine months ended September 30, 2021 was $7.8 million compared with adjusted net income of $606,000 for the nine months ended September 30, 2020.

 

EARNINGS/(LOSS) PER SHARE

 

 

●

Earnings per diluted share (GAAP) for the third quarter of 2021 was $0.00 compared with loss per share of $0.04 for the third quarter of 2020. Adjusted loss per share (non-GAAP) for the third quarter of 2021 was $0.19 compared with adjusted loss per share of $0.02 for the third quarter of 2020.

 

 

●

Earnings per diluted share (GAAP) for the nine months ended September 30, 2021 was $0.17 compared with $0.01 for the nine months ended September 30, 2020. Adjusted loss per share (non-GAAP) for the nine months ended September 30, 2021 was $0.20 compared with adjusted earnings per diluted share of $0.03 for the nine months ended September 30, 2020.

 

ADJUSTED EBITDA

 

 

●

Adjusted EBITDA, a non-GAAP measure, for the third quarter of 2021 was negative $2.1 million compared with positive $1.7 million for the third quarter of 2020.

 

 

●

Adjusted EBITDA, a non-GAAP measure, for the nine months ended September 30, 2021 was positive $4.4 million compared with positive $5.8 million for the nine months ended September 30, 2020.

 

CASH

 

 

●

Cash, cash equivalents and restricted cash as of September 30, 2021 were $75.2 million.

 

Troy Wichterman, Chief Financial Officer, remarked, “In the quarter, we significantly increased revenue from our high margin biopreservation media products. We believe that our focus on reducing the cost variances and warranty expense associated with our Stirling ULT products will positively impact gross margin and that we will continue to show improvement in gross margin over the next several quarters.”

 

Page 4 of 13
 

 

a01.jpg
 
a02.jpg

 

2021 Revenue Guidance

 

BioLife today updated 2021 revenue guidance, which is based on current expectations for its existing business.

 

Total revenue for 2021 is now expected to range from $115 million to $119 million up from previous guidance of $108 million to $117 million, reflecting year-over-year growth of 139% to 147%.

 

Total revenue expectations for 2021 include the following contributions:

 

 

●

Cell processing platform; $42 million to $43 million, an increase of 36% to 39% over the prior year.
 

●

Freezers and Thaw Systems platform; $57 million to $59 million, an increase of 321% to 335% over the prior year.
 

●

Storage and Cold Chain Services platform; $16 million to $17 million, an increase of 345% to 373% over the prior year.

 

Conference Call & Webcast

 

Management will discuss the Company's financial results and provide a general business update on a conference call and live webcast today at 4:30 p.m. ET (1:30 p.m. PT).

 

To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at http://www.biolifesolutions.com/earnings. Alternatively, you may access the live conference call by dialing 1 (844) 825-0512 or 1 (315) 625-6880 and use Conference ID 7075159. A webcast replay will be available approximately two hours after the call and will be archived on http://www.biolifesolutions.com/ for 90 days.

 

 

About BioLife Solutions

 

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services. Our portfolio includes our proprietary CryoStor® freeze media and HypoThermosol® shipping and storage media, ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system, Custom Biogenic Systems® high-capacity storage freezers, SciSafe biologic materials storage, Stirling Ultracold ULT freezers, and, upon closing of our acquisition of Sexton, Sexton cell processing tools. For more information, please visit www.biolifesolutions.com, www.scisafe.com, www.stirlingultracold.com and www.sextonbio.com and follow BioLife on Twitter.

 

Page 5 of 13
 

 

a01.jpg
 
a02.jpg

 

Cautions Regarding Forward Looking Statements

 

Except for historical information contained herein, this presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the expected financial performance of the company following the completion of its recent acquisitions and giving effect to the COVID-19 pandemic, the company's ability to implement its business strategy and anticipated business and operations, in particular following its acquisitions of Stirling Ultracold and Sexton Biotechnologies, the expected synergies between the company, Stirling Ultracold, and Sexton Biotechnologies, the company’s ability to realize all or any of the anticipated benefits associated with its recent acquisitions, the potential utility of and market for the company's products and services and the company’s ability to cross sell its products and services, including its recently acquired products, guidance for financial results for 2021 and beyond, including regarding Stirling Ultracold and Sexton Biotechnologies revenue, and potential revenue growth and changes in gross margin, adjusted gross margin and adjusted EBITDA, and potential market expansion, including with consideration to our recent acquisitions and giving effect to the COVID-19 pandemic, the company's anticipated future growth strategy, including the acquisition of synergistic cell and gene therapy manufacturing tools and services or technologies, regulatory approvals and/or commercial manufacturing of our customers' products, and potential customer revenue. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, unexpected costs, charges or expenses resulting from the acquisition of Stirling Ultracold and Sexton Biotechnologies (or from the company’s 2019 and 2020 acquisitions), market adoption of the company’s products (including the company’s recently acquired products including the products of Stirling Ultracold and Sexton Biotechnologies), the ability of the Stirling Ultracold and Sexton Biotechnologies acquisition (or the company’s 2019 and 2020 acquisitions) to be accretive on the company’s financial results, the ability of the company to continue to implement its business strategy, uncertainty regarding third-party market projections, market volatility, competition, litigation, the impact of the COVID-19 pandemic, and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law

 

Non-GAAP Measures of Financial Performance:

 

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: adjusted gross profit and gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), adjusted earnings per diluted share (EPS), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release. When analyzing the Company's operating results, investors should not consider non-GAAP measures as substitutes for the comparable financial measures prepared in accordance with GAAP.

 

Page 6 of 13
 

 

a01.jpg
 
a02.jpg

 

Media & Investor Relations

    

At the Company

Roderick de Greef

President and Chief Operating Officer

    

(425) 686-6002

    

rdegreef@biolifesolutions.com

    

 

Investors

 

LHA Investor Relations

Jody Cain

(310) 691-7100

jcain@lhai.com

 

Page 7 of 13
 

 

a01.jpg
 
a02.jpg

 

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, amounts in thousands, except share and per share amounts)

 

   

Three Months Ended

    

Nine Months Ended

  
   

September 30,

    

September 30,

  

(In thousands, except per share and share data)

  

2021

    

2020

    

2021

    

2020

  
                                 

Product revenue

   $ 29,201     $ 10,804     $ 70,445     $ 32,020  

Service revenue

     2,250       -       6,417       -  

Rental revenue

     2,349       475       4,989       1,341  

Total revenue

     33,800       11,279       81,851       33,361  

Costs and operating expenses:

                                

Cost of product, rental, and service revenue (exclusive of intangible assets amortization)

     24,864       4,826       50,968       13,893  

Research and development

     3,219       1,725       8,250       4,865  

Sales and marketing

     4,065       1,588       9,228       4,530  

General and administrative

     10,081       3,503       22,058       9,916  

Intangible asset amortization

     2,525       706       5,340       2,100  

Acquisition costs

     345       179       1,616       417  

Change in fair value of contingent consideration

     (140 )     (2 )     1,086       (1,528 )

Total operating expenses

     44,959       12,525       98,546       34,193  

Operating loss

     (11,159 )     (1,246 )     (16,695 )     (832 )
                                 

Other income (expense), net

                                

Change in fair value of warrant liability

     -       (1,005 )     (121 )     4,467  

Change in fair value of investments

     -       1,110       -       1,110  

Interest (expense) income, net

     (194 )     13       (331 )     59  

Other expense

     (7 )     (5 )     (7 )     (9 )

Gain on acquisition of Sexton Biotechnologies, Inc.

     6,451       -       6,451       -  

Total other income

     6,250       113       5,992       5,627  
                                 

(Loss) income before income tax benefit

     (4,909 )     (1,133 )     (10,703 )     4,795  

Income tax benefit

     4,988       -       17,540       -  

Net income (loss)

   $ 79     $ (1,133 )   $ 6,837     $ 4,795  
                                 

Earnings (loss) attributable to common shareholders

                                

Basic

   $ 0.00     $ (0.04 )   $ 0.18     $ 0.17  

Diluted

   $ 0.00     $ (0.04 )   $ 0.17     $ 0.01  

Weighted average shares used to compute earnings (loss) per share attributable to common shareholders:

                                

Basic

     40,940,880       31,639,420       37,437,900       25,418,375  

Diluted

     43,325,549       31,639,420       39,987,599       29,412,538  

 

Page 8 of 13
 

 

a01.jpg
 
a02.jpg
 

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited, amounts in thousands, except per share amounts)

 

   

Three Months Ended

    

Nine Months Ended

  
   

September 30,

    

September 30,

  

(In thousands)

  

2021

    

2020

    

2021

    

2020

  
                                 

NET INCOME/(LOSS)

   $ 79     $ (1,133 )   $ 6,837     $ 4,795  

Other comprehensive loss

     (166 )     -       (163 )     -  

COMPREHENSIVE INCOME/(LOSS)

   $ (87 )   $ (1,133 )   $ 6,674     $ 4,795  

 

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION

(Unaudited, amounts in thousands)

 

   

September 30,

    

December 31,

  

(In thousands)

  

2021

    

2020

  

Cash, cash equivalents and restricted cash

   $ 75,151     $ 90,456  

Accounts receivable, net

     20,232       8,006  

Inventories

     29,696       11,602  

Total current assets

     130,505       114,712  

Total assets

     559,391       234,829  
                 

Accounts Payable

     14,296       3,672  

Total current liabilities

     35,793       15,573  

Total liabilities

     70,132       29,583  

Total shareholders' equity

   $ 489,259     $ 205,246  

 

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS INFORMATION

(Unaudited, amounts in thousands)

 

   

Nine Months Ended

  
   

September 30,

  

(In thousands)

  

2021

    

2020

  

Net cash (used in) provided by operating activities

   $ (3,819 )   $ 4,388  

Net cash used in investing activities

     (10,650 )     (2,658 )

Net cash (used in) provided by financing activities

     (673 )     100,806  

Effects of currency translation

     (163 )     -  

Net increase (decrease) in cash, cash equivalents and restricted stock

   $ (15,305 )   $ 102,536  

 

Page 9 of 13
 

 

a01.jpg
 
a02.jpg

 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP GROSS PROFIT TO NON-GAAP (ADJUSTED) GROSS PROFIT

(Unaudited, amounts in thousands)

 

   

Three Months Ended

    

Nine Months Ended

  
   

September 30,

    

September 30,

  

(In thousands)

  

2021

    

2020

    

2021

    

2020

  

GAAP GROSS PROFIT

   $ 8,301     $ 5,867     $ 29,075     $ 17,727  

GAAP GROSS MARGIN

     25

%

     52

%

     36

%

     53

%
                                 

ADJUSTMENTS TO GROSS PROFIT:

                                

Inventory step-up

     365       4       1,130       390  

Intangible asset amortization

     635       586       1,808       1,741  

ADJUSTED GROSS PROFIT

   $ 9,301     $ 6,457     $ 32,013     $ 19,858  

ADJUSTED GROSS MARGIN

     28

%

     57

%

     39

%

     60

%

 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP OPERATING EXPENSES TO NON-GAAP (ADJUSTED) OPERATING EXPENSES

(Unaudited, amounts in thousands)

 

   

Three Months Ended

    

Nine Months Ended

  
   

September 30,

    

September 30,

  

(In thousands)

  

2021

    

2020

    

2021

    

2020

  

GAAP OPERATING EXPENSES

   $ 44,959     $ 12,525     $ 98,546     $ 34,193  
                                 

ADJUSTMENTS TO OPERATING EXPENSES:

                                

Cost of product, rental, and service revenue

     (24,864 )     (4,826 )     (50,968 )     (13,893 )

Acquisition costs

     (345 )     (179 )     (1,616 )     (417 )

Intangible asset amortization

     (2,525 )     (706 )     (5,340 )     (2,100 )

Loss on disposal of assets

     (7 )     -       (24 )     -  

Change in fair value of contingent consideration

     140       2       (1,086 )     1,528  

ADJUSTED OPERATING EXPENSES

   $ 17,358     $ 6,816     $ 39,512     $ 19,311  

 

Page 10 of 13
 

 

a01.jpg
 
a02.jpg

 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP OPERATING INCOME (LOSS) TO NON-GAAP (ADJUSTED) OPERATING INCOME (LOSS)

(Unaudited, amounts in thousands)

 

   

Three Months Ended

    

Nine Months Ended

  
   

September 30,

    

September 30,

  

(In thousands)

  

2021

    

2020

    

2021

    

2020

  

GAAP OPERATING INCOME/(LOSS)

   $ (11,159 )   $ (1,246 )   $ (16,695 )   $ (832 )
                                 

ADJUSTMENTS TO OPERATING INCOME/(LOSS):

                                

Inventory step-up

     365       4       1,130       390  

Acquisition costs

     345       179       1,616       417  

Intangible asset amortization

     2,525       706       5,340       2,100  

Loss on disposal of assets

     7       -       24       -  

Change in fair value of contingent consideration

     (140 )     (2 )     1,086       (1,528 )

ADJUSTED OPERATING INCOME/(LOSS)

   $ (8,057 )   $ (359 )   $ (7,499 )   $ 547  

 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP NET INCOME (LOSS) TO NON-GAAP (ADJUSTED) NET INCOME (LOSS)

(Unaudited, amounts in thousands)

 

   

Three Months Ended

    

Nine Months Ended

  
   

September 30,

    

September 30,

  

(In thousands)

  

2021

    

2020

    

2021

    

2020

  

GAAP NET INCOME/(LOSS)

   $ 79     $ (1,133 )   $ 6,837     $ 4,795  
                                 

ADJUSTMENTS TO NET INCOME/(LOSS):

                                

Inventory step-up

     365       4       1,130       390  

Acquisition costs

     345       179       1,616       417  

Intangible asset amortization

     2,525       706       5,340       2,100  

Loss on disposal of assets

     7       5       24       9  

Change in fair value of contingent consideration

     (140 )     (2 )     1,086       (1,528 )

Change in fair value of investments

     -       (1,110 )     -       (1,110 )

Change in fair value of warrant liability

     -       1,005       121       (4,467 )

Gain on acquisition of Sexton Biotechnologies, Inc.

     (6,451 )     -       (6,451 )     -  

Income tax benefit

     (4,988 )     -       (17,540 )     -  

ADJUSTED NET INCOME/(LOSS)

   $ (8,258 )   $ (346 )   $ (7,837 )   $ 606  

 

Page 11 of 13
 

 

a01.jpg
 
a02.jpg

 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP NET INCOME (LOSS) PER DILUTED SHARE TO NON-GAAP (ADJUSTED) NET INCOME (LOSS) PER DILUTED SHARE

(Unaudited, amounts in thousands)

 

   

Three Months Ended

     Nine Months Ended  
   

September 30,

     September 30,  
   

2021

    

2020

    

2021

     2020  

GAAP NET INCOME/(LOSS) PER SHARE - DILUTED

   $ 0.00     $ (0.04 )   $ 0.17     $ 0.01  
                                 

ADJUSTMENTS TO NET INCOME/(LOSS) PER SHARE - DILUTED:

                                

Inventory step-up

     0.01       -       0.03       0.02  

Acquisition costs

     0.01       0.01       0.04       0.02  

Intangible asset amortization

     0.06       0.02       0.13       0.08  

Change in fair value of contingent consideration

     -       -       0.03       (0.06 )

Change in fair value of investments

     -       (0.04 )     -       (0.04 )

Change in fair value of warrant liability

     -       0.03       -       -  

Gain on acquisition of Sexton Biotechnologies, Inc.

     (0.15 )     -       (0.16 )     -  

Income tax benefit

     (0.12 )     -       (0.44 )     -  

ADJUSTED NET INCOME/(LOSS) PER SHARE - DILUTED

   $ (0.19 )   $ (0.02 )   $ (0.20 )   $ 0.03  

 

Page 12 of 13
 

 

a01.jpg
 
a02.jpg

 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP NET INCOME (LOSS) TO NON-GAAP (ADJUSTED) EBITDA

(Unaudited, amounts in thousands)

 

   

Three Months Ended

    

Nine Months Ended

  
   

September 30,

    

September 30,

  

(In thousands)

  

2021

    

2020

    

2021

    

2020

  

GAAP NET INCOME/(LOSS)

   $ 79     $ (1,133 )   $ 6,837     $ 4,795  
                                 

ADJUSTMENTS:

                                

Interest expense/(income), net

     194       (13 )     331       (58 )

Income tax benefit

     (4,988 )     -       (17,540 )     -  

Depreciation

     1,101       481       2,996       1,454  

Intangible asset amortization

     2,525       706       5,340       2,100  

EBITDA

   $ (1,089 )   $ 41     $ (2,036 )   $ 8,291  
                                 

OTHER ADJUSTMENTS:

                                

Share-based compensation (non-cash)

     4,868       1,560       8,892       3,818  

Inventory step-up

     365       4       1,130       390  

Acquisition costs

     345       179       1,616       417  

Loss on disposal of assets

     7       5       24       9  

Change in fair value of contingent consideration

     (140 )     (2 )     1,086       (1,528 )

Change in fair value of investments

     -       (1,110 )     -       (1,110 )

Change in fair value of warrant liability

     -       1,005       121       (4,467 )

Gain on acquisition of Sexton Biotechnologies, Inc.

     (6,451 )     -       (6,451 )     -  

ADJUSTED EBITDA

   $ (2,095 )   $ 1,682     $ 4,382     $ 5,820  

 

# # #

 

Page 13 of 13
 EX-101.SCH 3 blfs-20211111.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 blfs-20211111_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 blfs-20211111_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 blfs-20211111_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 a01.jpg begin 644 a01.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0 L17AI9@ 34T *@ @ 0$Q ( M * &@ !''EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3% MQL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! M 0$! 0$ ! @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! M @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D: M)BH*# MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3 MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:R?$'B M?2/#%E]IUJ]CMU(^1.KR'T51R:Q?'&M^(+>QFM_!45K=W\*YN8]X:>%2.&6+ M^+]?H:\5T;P1XM\?:I)=W8G56?$U]?%@!@\@ \DCI@<#IQ7H8;"1G'VE65HK M[S@Q&*E"7)3C=_@>Y^&/B'X>\6,8M-NC%<_\^UR DA'J!D@_@373U\Y^*/@_ MK_AM1>:5(=5MX_F,ENA26,COLR3^()_"NX^&'B#QC-9HWB6-#HV,1WM\_ERD M]@O>3/O^?:KKX2ER>UH3NNW4FCBJG-[.M&S[]#U2BBOGC5?B/\1K_P"*VI^% MO"UY;LT=W-';0O!$,*F3RS#T!ZUYAZ)]#T5\_:SXP^-7@JS_ +4\0V=G/8(R MB1S'$Z+DX /ED,,D@9^G-=C<>,O%GC7X6Z=K?PWLU359+OR[N!VB(C55%K ^)U":L8A]J5=N ^?\ 9^7\JUJ "BN ^,OB MK5O!_@5-2T&=8+HWD<19HU<;2K$C!&.PK%EUWXCZ[\+/#>K>#A'=:I=!FOF* MP("N2!@.0.W:@#UFBN"\>>.;_P !?#.TU2\MXYM9F6*W\N0C8)V3+D[>H&UN M ?3FHOA-JGC;7-+FU;QD]NUG>QQRZ>L2HI"DMNR%YZ;<9- 'H5%%% !17FFJ M^*/%/B?X@:CX4\$W-II4.DQHU]J5Q#YS[V&0J(>._?NIY'>OKS_$KP+IDNN/ MK]EXJL+0&2[MIK!+601]V4IZ#)Y]^#TH ]3HJAH>L6WB#0;+5K DV]Y"LJ;N MH!'0^XZ?A5_(W8SR><4 %%<[X_U>\T'P!K&J:9(([NUMR\3LH8 Y'8\&K'@[ M4;G6/!&BZE?N'N;NQAFE8*%#,R DX' Y- &U117'?%'QE>>!?!IUC3K>"XF^ MT)%LGSMPV>>"#VH [&BL3Q=%XAF\-SIX.GM[?52R>5)<@% -PW9R#VSVK7MA M*+6(7)!F"#S"O0MCG]: )** 0F_%::ZT^XEMKB.&(K)$Y5A\OJ*] M]CNI4T%+ORVN)5MA)L7K(VW.![DUX-\;=*OH?&[ZC);2"SN(8UCG"Y0L!@KG ML>.E=;X'^,VGW5O;:9XE06,Z*L:72\Q/@8&[NI_,?2O. M&Z58T9N$&1T%=YXC\:V&@,UN ;F] '[E> N1D;CV_G7FEH;[Q%XK6XC@,DTU MP)'$:_*@R/R ]Z6"I-.59QM&VAQYE64HPP\9BY/4=*^K:^4[K79_!W[06K>(&TNXO8[>_NO MW297?N#+PV#_ 'LUXA],C<^)FN_%>\\)RVOB[0+;3-'=T^U2V"B3(W @,?-? M W >G.!GFHO&$^AP_LX:$/!US<&W76%6=I?DE\TQ2EPX!P#R. 2,8ZU:\7?& MC5/&7ANZ\/Z-X/NXI+]/*9RS3,%)&0J!!R>F<\>E8WB'P1JWA7X 6D.J6\B7 MM[KZ7+6RC1(H# =#QD_4#K2 OZ]X]UJP^''@WPIX=N)(+[4[)7FN$?$A M5G9%0-U7)!R>O ]ZV]:^!-QH'A>YUS2/$^HMKUG ;AY-^U92@W$*1\P/!P23 M6#XA\#:U=?#OP9XM\/VLEQ=:99(EQ B9=521G1PO4@$D$#GIVSC=USX_Q:]X M3N='T?0-077+V!K=H]H9(RPVDK@[F/)P-HYQ0!S?B+QW>>-O@ 1J["34=/U6 M&&6; 'FJ4,EI,E&(S]ZEUGP!J/A+X!,=2M MV74M1U6&:2!5RT2*CA5.._)/MNQ2^.[6X?X!^!8T@D9U>3&?$YN[A[BXMK2T:!F!C $#-NQUW<54O;R?X7_ OTJX\.ZG>#4O%E MM')*[L"+6.-2-T7.!U)!4<=>30!R]QX>\*6GA4ZO9?$ MB4^*8[?SB%F.UY -QC4@;LYR V>O.*]C^"GC:\\:>"7;5Y/-U"PF,$LV /-7 M *L<=\''X9[UY3_PL7P%%H*P2?#>W/B$($,+6D8A,F,9Z[\$\[=OMGO7L?PJ MLKN'PN][J/AK3_#DUY('6TLH3&2@'RM(">&Y/'84P,_Q+\/=>A\93^+?A_K, M.GZE=(J7EK=IN@N, '@'!P!VZ\Y'-9MW\0O'7A:W=_'W@F*ZTP#;->Z5('5 M5Z$E"6X_WBHJ*/4=4^%'C?69=^%Q MGD"_K?QI\*7^BW5EX::YU[4KJ%HH;&WLI-O'20?#K M29? 4L2R^(+F.RL)40*(=Y(9MN.""-N.Q/M4D?P,\*-8C[APVL>_Q#HUZ-4CM^* .5FU[5)OA?X_P#"OB"Z-[?> M'E\I;Q_O3PL?D+>I^7D^XSSR60RR)KWP:1'94;3OF4' /[I.M/.@:M_PK/Q_ MXHURRDM+_P 1#S([)E^>&%3\@(ZY.[I["F:O!=:+X?\ A=XN-E<7-CHUHB7Z MPIN>)7B3#8]!ANO&<#O0!Z'\7':/X3:^\;%6%N,%3@CYUKRSXH:#8S_ OPQX MBE$K:BFG6%L',K;2AB+>M;_Q%^)>D>+OAUJ^G>#%NM7D>%3]22Q<#)/0 9Z^U,^(&FWM]^S-H,=G:RS26]G822(B$LJB( G'7C/- %O MXH^&=.\&?!/5K70!<01R74,K%[AY&W%T'5B2. .*?XFO]2\3^*?#W@#3-0FT M^TGTU;W5+FW;$K18P(P>V<<^NX>A!B^)GBBP\;_ O4K_ $$7$L:W4,3*\+(P M<.C$8(YP&'(XI_B>SU'PMXL\.^/["PFO[*+35LM4@MTW21QXR) ._7GL-H]< M@ N:W\&]%TK1KC4?!+WFC:W:QM/!:Z@G:X8D$'IP._?H>-\5>*-1\: M^%?AOJ-E$;CPEI?PKTB9?,N8=;26Z:,9"N\J,1D M=AG;GOB@#I_%?PA\/0>%=1U.WFU(:W:6TEQ'JDE]*TS2(I;)YV\D;;KL]F2)&C5MH+$U>Q^+06\%ZV%!).G MS@ =_P!VU>5>&?$>O>#OAEX-ODTUKSP_YK)' 7G@!D?:X&?N\\Y';'<4 M1P>'/!&H"VN?@[XFMM&UU)E=5>_E_?KW5XI"6/TQ[&O;80_EJTRH)B@$A3IG MV/7&2:\&\?:Y\,/%7AZ:#POIZ:AXBN%'V(:;I\DYH UZ***!$5S;07EL]O=PQSPR#:\ MA!ZUY5XK^"-INJT_3+/2K86^GVZ01 M]PHY;W)ZD_6K5%*I7J5(J,GHB*6%I4I.<5J]6_4****Q.D**** "D"*'+!0& M; )QR:6B@ HHHH **** &[$\S?M7>!C=CG'IFG444 %-6-$+%$52QRV!C)]: M=10 4FQ=^_:-P&-V.<>E+10 4444 (%"C"@ 9SP*6BB@ HHHH 0(JLQ50"QR AQ ZTM%% !1110 U8T1F9$568Y8@8S]:=110 4444 ?_9 end GRAPHIC 8 a02.jpg begin 644 a02.jpg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bioli20211111_8k_htm.xml IDEA: XBRL DOCUMENT 0000834365 2021-11-11 2021-11-11 false 0000834365 8-K 2021-11-11 BIOLIFE SOLUTIONS, INC. DE 001-36362 94-3076866 3303 Monte Villa Parkway, Suite 310 Bothell WA 98021 425 402-1400 false false false false BioLife Solutions, Inc. Common Shares BLFS NASDAQ false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document And Entity Information
Nov. 11, 2021
Document Information [Line Items]  
Entity, Registrant Name BIOLIFE SOLUTIONS, INC.
Document, Type 8-K
Document, Period End Date Nov. 11, 2021
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-36362
Entity, Tax Identification Number 94-3076866
Entity, Address, Address Line One 3303 Monte Villa Parkway, Suite 310
Entity, Address, City or Town Bothell
Entity, Address, State or Province WA
Entity, Address, Postal Zip Code 98021
City Area Code 425
Local Phone Number 402-1400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security BioLife Solutions, Inc. Common Shares
Trading Symbol BLFS
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0000834365
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.blfs.com/20211111/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports bioli20211111_8k.htm blfs-20211111.xsd blfs-20211111_def.xml blfs-20211111_lab.xml blfs-20211111_pre.xml ex_306474.htm http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bioli20211111_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "blfs-20211111_def.xml" ] }, "inline": { "local": [ "bioli20211111_8k.htm" ] }, "labelLink": { "local": [ "blfs-20211111_lab.xml" ] }, "presentationLink": { "local": [ "blfs-20211111_pre.xml" ] }, "schema": { "local": [ "blfs-20211111.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "blfs", "nsuri": "http://www.blfs.com/20211111", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bioli20211111_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.blfs.com/20211111/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bioli20211111_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.blfs.com/20211111/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001437749-21-026247-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-21-026247-xbrl.zip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